Paper Details

  1. Home
  2. Paper Details

Preferences of patients for benefits and risks of insomnia medications using data elicited during two phase III clinical trials.

Author: ChuaGin Nie, HeidenreichSebastian, Phillips-BeyerAndrea, RossMelissa, Seboek KinterDalma

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This discrete choice experiment (DCE) elicited patient preferences for medications for chronic insomnia. Daytime functioning was the most important benefit, while withdrawal symptoms were the most important risk. Patients were willing to trade-offs between benefits and risks, highlighting the importance of considering functional outcomes in treatment development.
Paper Details　
Original Abstract of the Article :
STUDY OBJECTIVES: To elicit the trade-offs patients are willing to make between benefits and risks of medications for chronic insomnia, with the purpose of allowing a patient-centric interpretation of clinical trial data. METHODS: A discrete choice experiment (DCE) was included in the two placebo-c...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644122/

データ提供：米国国立医学図書館（NLM）

Insomnia Medications: Understanding Patients' Preferences for Benefits and Risks

The search for effective and safe treatments for insomnia is a continuous journey through the desert of sleep disorders. This study explores the preferences of patients regarding the benefits and risks of insomnia medications. Utilizing a discrete choice experiment (DCE), the researchers collected data from 602 participants in two phase III clinical trials evaluating daridorexant, a medication for chronic insomnia. The study reveals that patients prioritize daytime functioning as a key benefit and withdrawal symptoms as a major concern.

Insomnia Medications: A Patient-Centric Approach to Treatment

This study underscores the importance of considering patient preferences when developing and evaluating insomnia medications. The research highlights the need for a patient-centric approach, taking into account their priorities and concerns. The findings suggest that improving daytime functioning should be a primary goal in treatment development, and that minimizing withdrawal symptoms should be a key consideration. This research calls for a more holistic understanding of insomnia and its impact on patients' lives, moving beyond simply focusing on sleep duration and latency.

Insomnia Medications: Navigating the Landscape of Sleep Disorders

This study offers valuable insights into the complex landscape of sleep disorders and the challenges faced by individuals with insomnia. The research emphasizes the importance of understanding patient preferences and concerns, and how these factors can influence treatment decisions. By taking a patient-centric approach, we can develop more effective and personalized treatment strategies for insomnia, ultimately leading to better sleep quality and improved well-being.

Dr.Camel's Conclusion

This study serves as a reminder that the desert of sleep disorders is vast and complex, and that understanding patient preferences is crucial in navigating this landscape. The research highlights the importance of prioritizing daytime functioning and minimizing withdrawal symptoms when developing and evaluating insomnia medications. By taking a patient-centric approach, we can provide more effective and personalized treatment options for insomnia, ultimately helping individuals find their way to a more peaceful and restful sleep.
Date :
  1. Date Completed 2022-11-10
  2. Date Revised 2022-11-23
Further Info :

Pubmed ID

36054921

DOI: Digital Object Identifier

PMC9644122

Related Literature

Article Analysis
・Effects of daridorexant
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.